The MoonRISe-3 Clinical Research Study
Learn about the MoonRISe-3 research study of an investigational drug delivery system for
adults with high-risk non-muscle invasive bladder cancer (HR-NMIBC)
The MoonRISe-3 Clinical Research Study
Learn about the MoonRISe-3 research study of an investigational drug delivery system for
adults with high-risk non-muscle invasive bladder cancer (HR-NMIBC)
The purpose of the study is to evaluate an investigational drug delivery system and its effects on bladder cancer. The investigational drug delivery system is not approved for use by any regulatory authority and is only available to patients in research studies like this one.
You may be considered for the MoonRISe-3 study, if you are 18 years of age or older:
- Have been diagnosed with high-risk non-muscle invasive bladder cancer after receiving Bacillus Calmette-Guérin (BCG)
- Are ineligible for or refuse radical cystectomy (surgery to remove the bladder)
The goal of this study is to find out if the investigational drug delivery system may help people whose bladder cancer has come back after BCG treatment & prevent it from coming back again.
Researchers want to see how well this treatment works, how safe it is, and how it compares to regular bladder chemotherapy.
Bladder cancer in general arises from the inner lining cells which are in direct contact with urine (called urothelial or transitional cells).
Non-muscle invasive bladder cancer, or NIMBC, is the early stage of bladder cancer where the tumor has yet grown only within the mucous membrane of the bladder. Thus, it has not yet grown into the thicker muscle wall of the bladder.
About 70% of cancers are discovered in this early stage.
Link: https://bcan.org/what-is-non-muscle-invasive-bladder-cancer/
See if you may qualify
Answer the following questions to see if you or someone you know may be eligible to take part in this study.
Please keep in mind: Even if you believe you meet the eligibility criteria, joining a clinical research study is not guaranteed. Whether you’re referred or able to take part depends on a review by a qualified healthcare professional. This questionnaire is intended for United States participants only.
Note about privacy: Email responses may not be encrypted. This means there’s a chance the messages could be seen by someone other than the intended recipient. We will avoid including sensitive personal information in emails whenever possible. However, we cannot guarantee that no sensitive information will be revealed indirectly.
About your information:
With your consent, we will use your answers to help determine whether you may be eligible for this clinical trial. You can withdraw your consent at any time.
Your information may be transferred to countries outside your country of residence, including the United States, which may have different data protection rules.
If you submit any personal information about someone else, you confirm that you have permission to do so.
Please read our Privacy policy for more details.